No Data
Huisheng Biotech: Report for the third quarter of 2024
Wuhan Hvsen Biotechnology (300871.SZ) released its performance for the first three quarters, with a net loss of 47.6583 million yuan.
Wuhan HVSen Biotechnology (300871.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters is 7...
Wuhan Hvsen Biotechnology (300871.SZ): a net loss of 47.6583 million yuan in the first three quarters.
Gelonghui, October 29th - Wuhan Hvsen Biotechnology (300871.SZ) released the third quarter report for 2024, achieving revenue of 0.793 billion yuan in the first three quarters, a year-on-year growth of 14.63%; net income attributable to shareholders of the listed company was -47.6583 million yuan; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was -32.3973 million yuan; basic earnings per share was -0.29 yuan.
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Huisheng Biotech: 2024 Semi-Annual Report Summary
Huisheng Biotech: 2024 Semi-Annual Report
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) 30% Jump Shows Its Popularity With InvestorsNo Data
No Data
